Results 121 to 130 of about 1,448,905 (180)

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors

open access: yes
This short review discusses about tyrosine kinase inhibitors (TyKI) as a potential targeting cell signalling pathway blocker playing active role as anticancer drugs.
Tasleem, Nasreen Sultana, Sushma Desai
core   +1 more source

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B‑Cell Signaling

open access: yesACS Omega, 2017
Einav Ratzon   +7 more
doaj   +1 more source

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. [PDF]

open access: yesMult Scler, 2023
Bar-Or A   +9 more
europepmc   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini   +19 more
wiley   +1 more source

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. [PDF]

open access: yesJ Immunother Cancer, 2023
Sinha M   +28 more
europepmc   +1 more source

TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. [PDF]

open access: yesAm J Hematol, 2022
Cherng HJ   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy